Recently, Viva Biotech's portfolio companies have new updates: QureBio, HAYA and Grove successfully completed financing; Arthrosi made solid progress in R&D; AmacaThera entered into a major collaboration.

01 Funding Process

QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing, Accelerating Clinical Progress in Global Competition for Core Pipelines
SHANGHAI, June 5, 2025 -- Qure Biotechnology (Shanghai) Co., Ltd. (QureBio), invested by Viva BioInnovator (VBI), announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 million (approximately USD 14 million) and was led exclusively by Efung Capital. This infusion of capital will be used to accelerate QureBio's clinical trials and advance its pipeline of novel antibody therapeutics. QureBio specializes in developing bispecific and multispecific antibody and protein therapeutics to address unmet medical needs in cancer, autoimmune diseases, and inflammatory disorders. The company has established a suite of proprietary technology platforms – including its I2T platform and its T-cell engager and NK-cell engager platforms – which form the foundation for its pipeline of novel drug candidates. Using these platforms, QureBio has built a robust pipeline of therapeutics aimed at previously intractable diseases.

HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
Switzerland and SAN DIEGO, USA - May 8, 2025 – HAYA Therapeutics, invested by Viva BioInnovator (VBI), a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has raised $65 million in Series A funding. The financing will accelerate the clinical development of HAYA's lead long non-coding RNA (lncRNA) targeting candidate HTX-001 in heart failure and the continued expansion of its RNA-guided regulatory genome pipeline development engine. This investment emphasizes investor confidence in HAYA's groundbreaking science and positions the company to deliver on its mission of bringing disease-modifying, precision medicines faster and more efficiently to patients. 

Grove Biopharma Closes $30 Million Series A Financing to Advance Bionic Biologics™, a New Therapeutic Modality
CHICAGO, Apr. 23, 2025 -- Grove Biopharma, invested by Viva BioInnovator (VBI), a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, announced the close of a $30 million Series A financing. The round was led by DCVC Bio with participation from Eli Lilly and Company, InVivium Capital, Walder Ventures, Gradiant Corporation, Mansueto Investments, and others. They join existing seed supporters, including Portal Innovations, where Grove was incubated. Proceeds will be used to further advance Grove Biopharma's proprietary platform and drive its lead oncology programs towards the clinic.

02 R&D Updates

Arthrosi Therapeutics Completes Enrollment in Pivotal Phase 3 REDUCE 2 Trial of AR882 for the Treatment of Gout and Tophaceous Gout
SAN DIEGO, March 5, 2025 -- Arthrosi Therapeutics, Inc., invested by Viva BioInnovator (VBI), a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, today announced the completion of enrollment for its pivotal global Phase 3 REDUCE 2 trial.

03 Key Collaboration

AmacaThera and Merck Animal Health Announce Collaboration in Animal Health
TORONTO, May 1, 2025 -- AmacaThera, invested by Viva BioInnovator (VBI), a clinical-stage biotechnology company specializing in drug delivery, announced it has signed a binding evaluation and option agreement with Merck Animal Health to develop long-acting formulations, for use in animal health. Built upon AmacaThera's unique hydrogel platform technology, AmacaGel™, products developed by AmacaThera are designed to enhance the sustained delivery of therapeutic agents with a single injection, potentially revolutionizing animal care and welfare in veterinary medicine. Both companies anticipate a fruitful collaboration, with the shared goal of advancing innovative animal health solutions, thereby enabling veterinarians to provide better care.

About QureBio
Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) is a biopharmaceutical company founded in 2017 and based in Shanghai, China. The company specializes in the research and development of innovative antibody and protein therapeutics, focusing on bispecific and multispecific antibodies for oncology, autoimmune diseases, and inflammatory disorders. QureBio has built multiple proprietary technology platforms for antibody discovery and engineering, enabling a robust pipeline of drug candidates aimed at addressing critical unmet medical needs in China and around the world.

About HAYA Therapeutics
HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its innovative platform to gain novel insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA's lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues. HAYA is headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities in San Diego. For more information on the company, please visit www.hayatx.com. 

About Grove Biopharma
Grove Biopharma is a private biotechnology company pioneering its proprietary Bionic Biologics™ platform to develop novel therapies targeting intracellular protein-protein interaction. Bionic Biologics represent a novel therapeutic modality that integrates principles of biologic and synthetic design. This innovative platform enables the targeting of well-validated yet previously intractable disease drivers, unlocking new possibilities for therapeutic intervention. A spinout from Northwestern University, Grove brings together a multidisciplinary team of chemists, biologists, materials scientists and entrepreneurs. The company is based in Chicago, embedded within the city's emerging life sciences ecosystem. For more information, please visit grovebiopharma.com.

About Arthrosi
Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing AR882, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with gout. AR882 has demonstrated encouraging efficacy and safety compared to SOC in Phase 2 studies as well as impressive results in achieving complete resolution of tophi in a Phase 2b study. Arthrosi is currently advancing AR882 in a pivotal Phase 3 program.

About AmacaThera
AmacaThera is a clinical-stage biotechnology company focused on advanced sustained-release hydrogel formulations designed to address critical challenges in therapeutic drug delivery. The Company's flagship platform, AmacaGel™, enables the development of long-acting therapies that enhance patient outcomes while minimizing systemic side effects. AmacaThera is driving innovation in key therapeutic areas, including pain management and oncology. For more information, please visit www.amacathera.com.